Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia

Area of Science:

• Hematology
• Oncology
• Transplantation Immunology

Background:

• T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis.
• Alemtuzumab achieves an 80% complete response (CR) but is often insufficient for long-term remission.
• Hematopoietic stem cell transplant (HSCT) is a consolidative therapy option for eligible T-PLL patients.

Purpose of the Study:

• To review the efficacy and complications of consolidative HSCT in T-cell prolymphocytic leukemia.
• To discuss critical aspects of patient selection for HSCT in T-PLL.
• To highlight pre- and post-transplant complications, including infections and graft-versus-host disease (GVHD).

Main Methods:

• Comprehensive literature review of studies reporting on HSCT for T-cell prolymphocytic leukemia.
• Analysis of data on treatment outcomes, including complete response rates and survival.
• Evaluation of reported complications, such as infections, acute GVHD, and chronic GVHD.

Main Results:

• Allogeneic HSCT is associated with significant risks, including increased infection rates and graft-versus-host disease (GVHD).
• Careful patient selection is crucial for optimizing HSCT outcomes in T-PLL.
• Atypical infections and GVHD represent key challenges in the post-transplant management of T-PLL patients.

Conclusions:

• Consolidative HSCT can be effective for T-PLL but requires meticulous management of its associated complications.
• Further research is needed to refine patient selection criteria and improve post-transplant care strategies.
• Optimizing HSCT protocols is essential for improving the long-term prognosis of T-cell prolymphocytic leukemia.